Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0016719 (
Friedreich's ataxia
)
2,098
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Background:
Friedreich's ataxia
(
FRDA
) is the most common autosomal recessive ataxia. Disease-modifying treatments are not available yet; however, several compounds are currently under investigation. As a result, there is a growing need for the identification of robust and easily accessible biomarkers for the monitoring of disease activity and therapeutic efficacy. The simultaneous measurement of multiple brain-derived proteins could represent a time- and cost-efficient approach for biomarker investigation in pathologically complex neurodegenerative diseases like
FRDA
.
Objectives:
To investigate the role of plasma
neurofilament-light
chain (NfL), glial fibrillary acidic protein (GFAP), total tau (t-tau) and ubiquitin C-terminal hydrolase L1(UCHL1) as biomarkers in
FRDA
. Additionally, NfL measurements derived from the novel multiplex assay were compared to those from an established NfL singleplex assay.
Methods:
In this study, an ultrasensitive Single molecule array (Simoa) 4-plex assay was used for the measurement of plasma NfL, GFAP, t-tau, and UCHL1 in 33
FRDA
patients and 13 age-matched controls. Differences in biomarker concentrations between these groups were computed and associations with genetic and disease related parameters investigated. Additionally, the agreement between NfL measurements derived from the 4-Plex and an established Simoa NfL singleplex assay was assessed.
Results:
Mean plasma NfL, GFAP and UCHL1 levels were significantly higher in
FRDA
patients than in controls (NfL:
p <
0.001; GFAP:
p
= 0.006, and UCHL1:
p
= 0.020). Conversely, there was no significant difference in concentrations of t-tau in the patient and control group (
p
= 0.236). None of the proteins correlated with the GAA repeat length or the employed measures of disease severity. The individual NfL values derived from the two assays showed a strong concordance (
r
c
= 0.93). Although the mean difference of 1.29 pg/mL differed significantly from 0 (
p
= 0.006), regression analysis did not indicate the presence of a proportional bias.
Conclusion:
This is the first study demonstrating that NfL, GFAP, and UCHL1 levels are raised in
FRDA
, potentially reflecting ongoing neuronal degeneration and glial activation. Further studies are required to determine their role as marker for disease activity and progression. Furthermore, the novel 4-plex assay appears to be a valid tool to simultaneously measure brain-derived proteins at extremely low concentrations in the peripheral circulation.
...
PMID:Plasma Markers of Neurodegeneration Are Raised in Friedreich's Ataxia. 3042 21